Sharda Cropchem Ltd

The transcript does not mention any current or planned fundraising through debt or equity for Sharda Cropchem Limited. Key points to note: - The company is stated as a zero-debt company with strong cash and liquid investments (INR 702 crores as of March 31, 2026). - No discussions or questions in the call indicated any plans for raising funds via debt or equity. - The company appears focused on organic growth through registrations and market expansion rather than external fundraising. - Management expressed confidence in their existing financial position and growth guidance without reference to capital raising. In summary, as per the available information on page 19 and related transcript, there is no indication of any impending or ongoing fundraising through debt or equity.

- For FY26, Sharda Cropchem's capital expenditure (CAPEX) stood at INR 505 crores. - No specific details on future or ongoing CAPEX/capital investments were explicitly mentioned in the transcript. - The company focuses on product registrations and expanding its market share globally, which may imply investment in registrations and marketing. - The business model emphasizes marketing and registrations rather than trading or manufacturing expansions. - Growth is expected from increasing registrations, market share, and leveraging an IP-led model, rather than large-scale CAPEX. - Any potential future strategic investments would relate to enhancing registrations and product pipelines, but no direct mention of new or planned capital investments was made.

- Revenue growth guidance for FY27 is expected to be 10% to 15%, with potential to go higher or lower based on various factors (Page 12, 13). - Volume growth projection for FY27 is around 15% (Page 13). - Growth is driven by both existing product portfolio and new registrations, though registration timelines are uncertain and approvals have slowed down (Page 11, 17-18). - Limited competition due to extended registration approval timelines may help in maintaining/improving realizations (Page 18). - Company has a global market share of about 5%, implying significant scope for market share expansion which can lead to business growth (Page 18). - Non-agro segment expected to grow 5%-10% with improving margins (Page 14). - New products launched in last 3-4 years contribute about 30% to revenue (Page 13). - Overall growth is supported by increasing global population and agricultural demand (Page 16).

- Revenue growth guidance for FY27 is expected between 10% to 15%, with potential to go higher or lower based on external factors. - Volume growth for FY27 is anticipated around 15%. - Gross margins are expected to remain stable around 35%, with some fluctuations possible. - EBITDA margin guidance for FY27 is maintained in the range of 18% to 20%. - EPS and PAT growth are likely to follow the revenue and margin trends, supported by strong operating performance. - The company is optimistic about continued product registrations impacting future growth but registration timing is uncertain. - Forex impacts are unpredictable and not factored into earnings guidance. - Overall, management is confident of sustaining healthy profitability through disciplined execution and market positioning.

- The transcript does not explicitly mention the current or expected order book or pending orders in quantitative terms. - However, the management indicates optimism regarding registrations and business growth despite uncertainties in registrations and approvals. - They mention having about 1,000 molecules currently under application for registration, expecting many registrations to come through in the financial year, though timing is uncertain due to bureaucratic processes. - The company emphasizes that growth is not solely dependent on new registrations but also on expanding market share from the current global share of about 5%. - They highlight strong customer confidence in their ability to supply promised products on time and at promised value, which supports business continuity. - Overall, while no specific order book figures are disclosed, the pipeline of registrations and customer trust underpin expected business growth.